Lantheus (NASDAQ:LNTH) Issues FY 2026 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 5.000-5.250 for the period, compared to the consensus EPS estimate of 4.990. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Truist Financial upped their price target on Lantheus from $89.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, April 15th. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. Citizens Jmp upped their price target on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 24th. Jefferies Financial Group reiterated a “buy” rating and issued a $110.00 price objective on shares of Lantheus in a report on Tuesday, March 17th. Finally, JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $88.86.

Lantheus Stock Up 0.4%

NASDAQ:LNTH opened at $86.15 on Thursday. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The stock’s fifty day moving average is $79.35 and its two-hundred day moving average is $68.62. Lantheus has a 52 week low of $47.25 and a 52 week high of $89.90. The stock has a market capitalization of $5.61 billion, a price-to-earnings ratio of 25.56 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The company had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts anticipate that Lantheus will post 4.26 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. UMB Bank n.a. raised its stake in shares of Lantheus by 104.1% in the fourth quarter. UMB Bank n.a. now owns 955 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 487 shares in the last quarter. Inceptionr LLC acquired a new stake in shares of Lantheus in the fourth quarter valued at $209,000. Advisory Services Network LLC acquired a new stake in shares of Lantheus in the third quarter valued at $120,000. New Vernon Capital Holdings II LLC acquired a new stake in shares of Lantheus in the third quarter valued at $147,000. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Lantheus in the third quarter valued at $224,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.